Stock Analysis

High Growth Tech Stocks in Asia for May 2025

SEHK:1061
Source: Shutterstock

As global markets experience volatility, with small- and mid-cap indexes facing significant declines amid renewed tariff threats and rising Treasury yields, the Asian tech sector continues to draw attention for its potential high growth opportunities. In this environment, identifying strong tech stocks involves looking for companies that demonstrate resilience through innovative solutions and adaptability in the face of economic uncertainties.

Advertisement

Top 10 High Growth Tech Companies In Asia

NameRevenue GrowthEarnings GrowthGrowth Rating
Suzhou TFC Optical Communication29.68%30.37%★★★★★★
Flaircomm Microelectronics30.38%34.37%★★★★★★
Fositek26.71%33.90%★★★★★★
Shanghai Huace Navigation Technology24.40%23.42%★★★★★★
Range Intelligent Computing Technology Group27.98%29.01%★★★★★★
eWeLLLtd24.95%24.40%★★★★★★
Nanya New Material TechnologyLtd22.72%63.29%★★★★★★
PharmaResearch24.38%25.85%★★★★★★
Park Systems21.52%22.58%★★★★★★
JNTC34.26%86.00%★★★★★★

Click here to see the full list of 496 stocks from our Asian High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Essex Bio-Technology (SEHK:1061)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Essex Bio-Technology Limited is an investment holding company that develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally with a market cap of HK$2.94 billion.

Operations: The company generates revenue primarily from its Surgical and Ophthalmology segments, contributing HK$879.90 million and HK$771.49 million, respectively. Additionally, it earns a smaller portion from the Provision of Services segment at HK$18.42 million.

Essex Bio-Technology has demonstrated resilience and adaptability in a dynamic market, evidenced by its recent dividend increase to HKD 0.06 per share and a successful phase 3 trial of its HLX04-O ophthalmic product. Despite the broader biotech industry experiencing faster growth rates, Essex's annual earnings have increased by 11.6%, with forecasts predicting further growth at an annual rate of 12%. The company's commitment to innovation is underscored by its R&D focus, aligning with regulatory changes and market demands in Asia’s competitive biotech landscape.

SEHK:1061 Revenue and Expenses Breakdown as at May 2025
SEHK:1061 Revenue and Expenses Breakdown as at May 2025

Raytron TechnologyLtd (SHSE:688002)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Raytron Technology Co., Ltd. focuses on the R&D, design, manufacturing, and sales of uncooled infrared imaging and MEMS sensor technology in China with a market cap of CN¥27.06 billion.

Operations: Raytron Technology Co., Ltd. specializes in developing and producing uncooled infrared imaging and MEMS sensor technologies. The company's operations are centered on the Chinese market, contributing to its substantial market capitalization of CN¥27.06 billion.

Raytron Technology has demonstrated robust growth, with a notable 16.3% annual increase in revenue and an impressive 24.7% surge in earnings projections per year, outpacing the broader Chinese market's averages. The company's commitment to innovation is evident from its recent deployment of an advanced thermal camera for medical applications, which has been integrated into critical neurosurgical procedures to enhance patient outcomes through superior blood flow visualization and accuracy. This technological advancement not only underscores Raytron's role in pushing the boundaries of medical imaging but also highlights its potential impact on healthcare technology globally. Moreover, the strategic share repurchases totaling CNY 100.27 million reflect a strong confidence in its financial health and future prospects.

SHSE:688002 Revenue and Expenses Breakdown as at May 2025
SHSE:688002 Revenue and Expenses Breakdown as at May 2025

Trend Micro (TSE:4704)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Trend Micro Incorporated is a company that specializes in developing and selling security-related software and services globally, with a market cap of ¥1.45 trillion.

Operations: The company generates revenue from selling security-related software and services across various regions, with significant contributions from Asia Pacific (¥113.95 billion) and Japan (¥86.22 billion). Notable revenue streams also include Europe and the Americas, contributing ¥67.37 billion and ¥70.57 billion respectively.

Trend Micro's strategic focus on integrating AI-driven security solutions with NVIDIA and AWS showcases its commitment to addressing the evolving needs of global enterprises. With a 6% annual revenue growth and a significant 16.2% projected increase in earnings, the company is poised for continued expansion, especially as it targets sectors like healthcare and finance that demand stringent data security. Recent initiatives include launching Trend Vision One™ for Sovereign Private Cloud to ensure data sovereignty, crucial in today's environment where digital jurisdiction is paramount. This move not only enhances their product offerings but also solidifies Trend Micro’s position in a competitive market by aligning with major tech partners to deliver comprehensive, real-time threat detection and prevention capabilities.

TSE:4704 Earnings and Revenue Growth as at May 2025
TSE:4704 Earnings and Revenue Growth as at May 2025

Where To Now?

  • Delve into our full catalog of 496 Asian High Growth Tech and AI Stocks here.
  • Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
  • Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Essex Bio-Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com